Related Experiment Video

Updated: May 7, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis

Hemant K Bid1, Ryan D Roberts, Parmeet K Manchanda

  • 1Corresponding Author: Peter J. Houghton, Center for Childhood Cancer, The Research Institute, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43205. Peter.Houghton@nationwidechildrens.org.

Molecular Cancer Therapeutics
|September 28, 2013
PubMed

Insights

This review highlights RAC1's role in cancer metastasis and angiogenesis. Targeting RAC1 inhibitors shows therapeutic potential for cancer treatment, offering new strategies against tumor growth and spread.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Angiogenesis and metastasis are crucial for cancer progression.
  • These processes involve complex cellular signaling networks, presenting therapeutic targets.
  • RAC1 is a key regulator of cell motility, implicated in tumor development.

Purpose of the Study:

  • To review the role of RAC1 in cell motility, tumor angiogenesis, and metastasis.
  • To summarize preclinical investigations of RAC1 inhibitors for cancer therapy.
  • To explore future directions and challenges in targeting RAC1 for cancer treatment.

Main Methods:

  • Literature review focusing on RAC1's function in cancer.
  • Analysis of preclinical data on RAC1 inhibitors.
  • Exploration of molecular and cellular mechanisms of RAC1 signaling.

Main Results:

  • RAC1 significantly regulates cell motility, impacting tumor angiogenesis and metastasis.
  • Preclinical studies demonstrate the therapeutic potential of RAC1 inhibitors.
  • Understanding RAC1 mechanisms offers insights into novel therapeutic targets.

Conclusions:

  • RAC1 is a critical target for inhibiting cancer angiogenesis and metastasis.
  • Targeting RAC1 signaling pathways presents a promising therapeutic strategy.
  • Further research into RAC1 mechanisms can lead to advanced cancer treatments.

More Related Videos

Discovery of Metastatic Regulators using a Rapid and Quantitative Intravital Chick Chorioallantoic Membrane Model07:03

Discovery of Metastatic Regulators using a Rapid and Quantitative Intravital Chick Chorioallantoic Membrane Model

Published on: February 3, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...